Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood-Based Small RNA Assay Predicts Survival After Lung Cancer Treatment

By LabMedica International staff writers
Posted on 29 Oct 2026

Locally advanced, non-resectable stage III lung cancer includes patients whose outcomes can vary substantially after curative-intent treatment. More...

Progression-free and overall survival are therefore important for assessing treatment strategies and identifying higher-risk patients. To improve this risk assessment, a newly presented blood-based small RNA approach shows potential to stratify survival following chemoradiotherapy.

Hummingbird Diagnostics GmbH (Heidelberg, Germany) presented findings on blood-based small RNA biomarkers for lung cancer treatment monitoring at ESMO Congress 2026 in Madrid, Spain. The research was conducted in collaboration with LungenClinic Grosshansdorf in Germany and University Hospital and Polyclinic F.D. Roosevelt in Banská Bystrica, Slovakia. The clinical study evaluated whether small RNA biomarkers could help predict survival outcomes in patients with locally advanced, non-resectable stage III lung cancer.

The study included 109 patients, 60 of whom underwent curative-intent chemoradiotherapy. This treatment group included 43 patients with non-small cell lung cancer and 17 with small cell lung cancer. Using a digital PCR (dPCR)-based classification approach, the researchers stratified patients who received chemoradiotherapy into high-risk and low-risk groups.

The two groups showed significantly different progression-free and overall survival outcomes. Median progression-free survival was 14 months in the low-risk group compared with seven months in the high-risk group, while median overall survival was 32 months versus nine months, respectively.

The biological mechanism underlying the assay was described as revealing new aspects of ribosome function that fuel cancer development. This work was recently presented at the EMBL-sponsored symposium, The complex life of RNA, held from October 13–16, 2026.

“We aim to translate biologically grounded small RNA information into practical blood-based assays that could complement clinical and radiological assessment and help inform future clinical decision-making. Such an approach could offer a cost-effective additional monitoring opportunity suitable for broader clinical implementation, with the potential to support clinical assessment and future treatment management,” said Dr. Rastislav Horos, Chief Technology Officer of Hummingbird Diagnostics.

Related Links
Hummingbird Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.